News
If approved, Regeneron's siRNA therapy will join the myasthenia gravis market alongside AstraZeneca’s dominant drugs ...
A new release of Phase III data in diabetic patients related to Eli Lilly’s orforglipron signals a positive turnaround for ...
WCG has introduced Total Training, a clinical trial solution designed to reduce protocol deviations and enhance site ...
Both gumokimab and manfidokimab met their primary endpoints, as Akeso oversees NDAs with the NMPA for both drugs.
Lighthouse secured a grant of $49.2m from the National Institute on Aging (NIA) to facilitate study of LHP588 for Alzheimer's ...
BlossomHill Therapeutics has dosed the first subject in the expansion cohorts of the SOLARA Phase I/II trial to evaluate ...
As regulators push to phase out animal testing, Charles River’s Steve Bulera notes that widespread implementation of ...
If approved, AbbVie's Rinvoq could be set to dominate the alopecia market after exhibiting better efficacy than main ...
The long-term data supports the drug’s progression into the HEALEY ALS Platform trial, with NUZ-001 dosing set to commence in ...
Dynavax has revealed outcomes from the initial part of its Phase I/II trial, comparing its shingles vaccine Z-1018 against ...
This webinar offers essential tools and insights to help organisations confidently navigate the BioSecure Act, ensuring they ...
UK-based Monument Therapeutics has joined forces with the Foundation for the National Institutes of Health (FNIH), US, to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results